HALRIC Hanseatic Life Science Research Infrastructure Consortium

🕚 Only eleven days left to MVA's event about research infrastructures and industry. There will be speakers and participants from all sectors - companies, infrastructures, and universities - and therefore also lots of opportunities for networking and finding your next collaboration partner! Perhaps you can already design a small feasibility study together and apply for funding from HALRIC, where we are actively looking to financially support more pilot studies that involve a company 🌟 See the program and sign up ➡️ https://lnkd.in/diU2uVu2 Emanuel Larsson, Pernille Rose Jensen, Björn Walse, Andreas Bøggild Maryam Olsson, Stephan Bouman, Veronica Lattanzi, PhD, Maria Sundh, Kajsa M Paulsson, Medicon Valley Alliance

In HALRIC we welcome the new and updated national Life Science strategies for Denmark and Sweden respectively (links in comments below). These forward-looking strategies highlight several shared objectives between the countries, paving the way for synergies in enhancing collaboration, fostering innovation, and leveraging health data on national and international scales. As a cross-border initiative spanning Denmark, Germany, Norway, and Sweden, HALRIC is uniquely positioned to support and contribute to several key objectives in both strategies: 🤝 Strengthened collaboration across research institutions, healthcare, and industry  In HALRIC we connect clinical, research, and industry partners with Research Infrastructures to drive health research and innovation. Our work transcends borders, fostering collaboration across the Nordic and German regions! 💻 Advanced use of health data and digital infrastructures  Both strategies emphasize unlocking the potential of health data (the Nordic gold mine) and leveraging Artificial Intelligence to translate this resource into innovations. Within the framework of HALRIC we are developing the Hanseatic Science Cloud (HSC), a cloud solution for managing and analyzing large and complex datasets – accelerating the transformation of data into health solutions. 💡 Innovation in healthcare  Through HALRIC we contribute to accelerating the adoption of new advanced analytical techniques in healthcare. By fostering collaborations between hospitals and advanced Research Infrastructures, HALRIC is making strides towards enhancing cancer surgery outcomes, improving treatment for severe asthma, and advancing therapies and diagnostics for neurodegenerative diseases like Parkinson’s. 🌍 International partnerships and global competitiveness  The HALRIC project is aligned with both strategies and exemplifies the value of international cooperation, uniting 21 partners across 4 countries. Together we harness the critical mass of expertise and advanced Research Infrastructures needed to stay at the forefront on the global stage.  We’re excited about the potential for HALRIC to not only align with these national strategies but to amplify their impact. Together, we are building a stronger Life Science ecosystem for the Northern Europe, driving impactful health research and innovations. Follow HALRIC Hanseatic Life Science Research Infrastructure Consortium for more news and updates! HALRIC partners: Lund University MAX IV Laboratory European Spallation Source ERIC Malmö University Region Skåne Skånes universitetssjukhus (Skåne University Hospital) Medicon Village University of Oslo University of Hamburg Universitätsklinikum Hamburg Eppendorf DESY EMBL European XFEL Freie und Hansestadt Hamburg Life Science Nord Medicon Valley Alliance DTU - Technical University of Denmark Københavns Universitet - University of Copenhagen Syddansk Universitet - University of Southern Denmark Aarhus University Rigshospitalet

Do you work in a life science company, or are you a researcher curious to collaborate with a life science company? Then don't miss out MVA's next network event on research infrastructures!

InfraLife's Feasibility Call offers Swedish researchers and infrastructure staff a unique chance to access advanced Life Science Research Infrastructures in Sweden. This call encourages collaboration, enabling participants to explore more than one infrastructure. Learn more about how to apply and take advantage of this unique chance to advance your research goals with state-of-the-art resources! #InfraLife #HALRIC #ResearchInfrastructures #LifeScience MAX IV Laboratory SciLifeLab European Spallation Source ERIC

We’re thrilled to welcome Veronica Lattanzi, PhD to the HALRIC Hanseatic Life Science Research Infrastructure Consortium team as our new Industry Engagement Manager!   In today’s competitive landscape, continuous innovation is key to success in Life Science. With a vibrant Life Science community and access to a wealth of advanced research infrastructures across the Öresund-Kattegat-Skagerrak-Hamburg region, HALRIC is well-positioned to drive impactful advancements. Veronica’s role will be to help HALRIC tap into this potential, connecting industry innovation with the region’s technological resources.   Working closely with our HALRIC Ambassadors and Science Clusters, Veronica will participate in assessment meetings to engage industry stakeholders in collaborative pilot projects, leveraging the potential of our regional advanced research infrastructures.   Veronica brings expertise in protein science, fostering cross-border collaborations, leading multi-partner projects, and developing frameworks for industry-EU research infrastructure partnerships. In her role with HALRIC, Veronica will play a key role in promoting pilot project calls towards industry to help achieve the goal of 35 pilot projects including industry collaboration.   We’re excited about the opportunities this addition brings to our team and network as Veronica’s expertise will help us continue building strong industry-research connections across the region.   Join us in welcoming Veronica to HALRIC and celebrating this step forward in fostering collaboration! HALRIC partners: Lund University, MAX IV Laboratory, European Spallation Source ERIC, Malmö University, Region Skåne, Skånes universitetssjukhus (Skåne University Hospital), Medicon Valley Alliance, Medicon Village, Universitetet i Oslo (UiO) | University of Oslo, University of Hamburg, Universitätsklinikum Hamburg Eppendorf, DESY, EMBL, European XFEL, Freie und Hansestadt Hamburg, Life Science Nord, DTU - Technical University of Denmark, Faculty of Health and Medical Sciences, UCPH, Syddansk Universitet - University of Southern Denmark, Aarhus University, Rigshospitalet

We are very happy that we already have a number of pilot projects that include life science industry, and we have place for many more! Are you curious what that could mean for you? HALRIC-partner Medicon Valley Alliance will focus its upcoming R&D member meeting on research infrastructures, and particularly how companies and researchers can benefit from using these - so make sure to check out the link below, and share it with your contacts and collaborators! At the meeting we will look at how companies can use advanced research infrastructures, what types of infrastructures are available, and how companies and academic researchers can join forces and get support for feasability studies to understand a specific infrastructure and its potential for R&D. See you on 10 December? Sign up at the link! ➡ https://lnkd.in/diU2uVu2 #overgransen #lifescience #researchinfrastructures #mediconvalley Katrine Brems Olsen, Anette Steenberg, Stephan Bouman, Emanuel Larsson, Pernille Rose Jensen, Andreas Bøggild, Maryam Olsson, Veronica Lattanzi, PhD, Kajsa M Paulsson, Maria Sundh Lund University, DTU - Technical University of Denmark, Aarhus University, MAX IV Laboratory

This month HALRIC reached a milestone with a total of 39 approved pilot projects, which has taken us more than halfway towards the goal of reaching 75 cross-border collaborations by 2026🎯🎉 Today we feature a pilot project, which contributes to optimizing time-resolved crystallography techniques at MAX IV Laboratory. The results could enhance our understanding of LPMO enzymes and lead to industrial applications in biofuels and new strategies for combating pathogens. The collaboration also builds on the Department of Chemistry, University of Copenhagen - UCPH's extensive knowledge and crystallographic studies of Lytic polysaccharide monooxygenases (LPMOs). The LPMO enzymes have a characteristic copper site being able to degrade recalcitrant polysaccharides, as well as additional implications in microbial pathogenesis of humans and important crop plants. Single crystal structure studies of microbial LPMOs at cryo-temperatures have been instrumental in elucidating their structure-function relationship, and have been the basis for mutagenesis, protein engineering and computational chemistry aimed at understanding the details of the reaction. Serial crystallography emerges as a promising technique to capture the dynamic process of LPMOs’ action in a time-resolved manner, as it can be carried out at room temperature, potentially providing a deeper understanding of their catalytic mechanism at the molecular level. This knowledge could lead to optimized industrial applications and innovative strategies in pathogen control. In order to use serial crystallography for a time-resolved study, the reaction must be triggered in a controlled manner, and the triggering mechanism is a specific focus of this pilot project collaboration between Leila Lo Leggio, Mohannad Aloula, Yusuf Theibich, Zhiyu Huang, Jie Nan, Monika Bjelcic. If this has inspired you to become a partner in a HALRIC pilot project, the next call for proposals ends on 28 November and you can find further info here: https://lnkd.in/dZANC__8

Innovation is key to staying competitive in Life Sciences. I was thrilled to attend the ESS/MAX IV Summit 2024 today at GoCo Health Innovation City and the new Mölnlycke Health Care Headquarters! The GoCo area is brimming with innovation potential, and there were many valuable takeaways on how world-class Research Infrastructures like the European Spallation Source ERIC and MAX IV Laboratory can further strengthen Swedish Life Science.   Advanced Research Infrastructures hold great potential in advancing medicine by detecting new drug targets, refining drug candidates, and improving drug delivery systems. As modern medicinal products become increasingly complex and difficult to administer, the use of advanced Research Infrastructures can unlock even greater value—speeding up R&D and making the drug development process more efficient and safer, as Marianna Yanez Arteta pointed out.   To enhance our innovation efforts by maximizing the potential of Research Infrastructures, I took note of the following key points:   ⬆️ The pandemic showed us—with the development of mRNA-based treatments—that the future relies on leveraging the synergies that emerge from collaborations between industry, academia, research infrastructures, and hospitals, as discussed by Hanna Barriga.   ⬆️ The capacity to store and analyze vast datasets continues to be a bottleneck, as mentioned by Pia Kinhult.   Although this was a Swedish event, the key messages I took away apply on a global scale. In the #HALRIC project, we are working to accelerate and broaden the use of advanced Research Infrastructures in the Öresund-Kattegat-Skagerrak-Hamburg area.   🔬 We offer support to pilot projects, particularly for industry and clinicians, with a focus on utilizing advanced Research Infrastructures in Life Science. We believe a triple-helix approach is crucial for fostering innovation.   💡 As part of HALRIC, the Hanseatic Science Cloud is being developed as a cloud-based solution for managing, handling, and analyzing large and complex datasets.   You can learn more about HALRIC and how to apply for a HALRIC pilot project on our website: https://lnkd.in/dfVwHeYZ   Kajsa M Paulsson Magnus Larsson Esko Oksanen Selma Maric Medicon Valley Alliance   #HALRIC #overgransen

With antibacterial resistance predicted to become the leading cause of mortality, the need for new antibiotics has never been more urgent. Antimicrobial peptides (AMPs) offer a promising alternative due to their high potency, but their clinical use has been limited by challenges like cytotoxicity and susceptibility to peptide degrading enzymes. While it is largely accepted that AMPs perturb the bacterial cell membrane, there is little consensus of how they do this.⁉️ Our latest #HALRIC pilot project aims to unlock some of the secrets of how AMPs interact with bacterial membranes. Using a novel combination of Small Angle X-ray Scattering (#SAXS) and Fluorescence Spectroscopy, the researchers will map the insertion of several different AMPs into the membrane, while simultaneously tracking the membrane leakage. This will allow them to directly link the structural effects to the perturbation of the lipid membrane, which is an essential step.🔬 This approach may contribute to developing AMP-based antibiotics to combat resistant infections and reduce the impact of infectious diseases - especially in vulnerable populations. Click below for more info about the cross-border pilot project, which is run by Reidar Lund, Vladimir Koynarev, University of Oslo and Cedric Dicko, Lund University, MAX IV Laboratory. AND stay tuned for more features of HALRIC pilot projects and be aware of the next deadline on 28 November, if you want to send in a proposal🚀 #AntimicrobialResistance #AMP #InfectiousDiseases #LifeSciences #ResearchCollaboration #HALRIC

💡During the COVID-19 pandemic, mRNA vaccines - powered by lipid nanoparticles (LNPs) - saved millions of lives. But there's still work to be done! Current LNP formulations can trigger unwanted immune responses and may contain "empty" particles that reduce the effectiveness of mRNA delivery. 🧬 One of the latest HALRIC pilot projects aims to tackle these challenges by understanding how different types of LNPs in a single formulation impact their structure and function. By reducing the number of empty LNPs, the cross-border research team want to pave the way for more efficient mRNA therapies. 🔬 The researchers from Department of Pharmacy, University of Copenhagenand Lund University are using advanced techniques like Asymmetric Flow Field-Flow Fractionation and Small Angle X-ray Scattering to study the structure of LNPs and measure their mRNA content, and assess how much protein each produces. Linking these insights can help design optimized LNPs for mRNA delivery. Find out more about this pilot project: https://lnkd.in/d8V7hHaT Federica Sebastiani, Abhijeet Lokras, Camilla Foged, Zhenning Shi, Lars Nilsson, Anna-Maria Börjesdotter, Hans Bolinsson, Ann Terry, Fátima Herranz-Trillo, MAX IV Laboratory. #HALRIC #SAXS #mRNA #LNP #lifesciences #research #overgransen